9 results about "TLR2" patented technology

The application discloses a caviar polypeptide composition with enhanced immune function, a preparation method, application and preparation, belongs to the technical field of bioactive polypeptides, and comprises at least one polypeptide with an amino acid sequence of RWFPGKPLFWRA, FWKPLRGALFPW or KWRFPGALPWFA and a molecular weight of 1400-1550 Da. The preparation method comprises caviar protein extraction, complex enzymolysis, ultrafiltration separation, chromatography purification and solid-phase synthesis. Animal experiments prove that the polypeptide can significantly enhance cell immunity, humoral immunity, monocyte-macrophage function and NK cell activity, the mechanism is related to TLR2 / TLR4 receptor activation and NF-κB / MAPK signal pathways, the safety is good, and the polypeptide is suitable for development into an immune-enhancing health food or medicine.

The application discloses a targeted acne-removing composition suitable for sensitive skin and a preparation method and application thereof. The targeted acne-removing composition comprises lysozyme, a first extract and a second extract in a mass ratio of 1:(0.1-10):(0.1-5). The first extract comprises guaiacum extract and myrtle fruit extract. The second extract comprises sophora flavescens extract and angelica sinensis extract. The targeted acne-removing composition containing lysozyme, the first extract and the second extract in specific mass ratios can inhibit the activity of propionibacterium acnes, down-regulate the expression of Toll-like receptor 2 (TLR2) and Toll-like receptor 4 (TLR4), and achieve efficient acne removal, and has the mild property and can be suitable for sensitive skin.

The application provides an E. coli outer membrane vesicle targeting TLR2 receptor and a construction method thereof, and relates to the technical field of biological medicine. The application first constructs a ClyA-HLYV fusion protein, and successfully obtains a recombinant plasmid ClyA-HLYV-pGEX-6P-1 stably expressing the fusion protein through genetic engineering technology, and induces endogenous expression of the fusion protein in an E. coli W3110 strain, to prepare a targeted bacterial outer membrane vesicle (HLYV-OMVs) expressing the ClyA-HLYV fusion protein on the surface. The HLYV-OMVs prepared by the application not only retain the specific recognition ability of HLYV to the surface TLR2 receptor of breast cancer cells, but also have the potential to encapsulate drugs, realizing the dual functions of targeted recognition and drug delivery. In addition, the HLYV-OMVs effectively solve the key problem of long-acting time of HLYV single peptide in targeted application, have good stability, significantly accelerate the effect starting speed after HLYV combines with the receptor, and lay an important foundation for efficient targeted treatment of tumors.

The application discloses an IGF2BP2-m6A-VCAN-TLR2 signal axis in the preparation of a drug for treating intrahepatic cholangiocarcinoma lymphatic metastasis. In view of the problems of unknown intrahepatic cholangiocarcinoma lymphatic metastasis mechanism and lack of effective target, the application finds and verifies a new pathway that from insulin-like growth factor 2 mRNA binding protein 2, m6A modification regulates the expression of multi-functional proteoglycan, and then activates Toll-like receptor 2 signal, promotes macrophage secretion of vascular endothelial growth factor C and drives lymphatic metastasis. Based on this, the application provides an inhibitor targeting the signal axis, in particular, a small molecule compound 8010-8498. Experiments show that the compound can significantly inhibit cholangiocarcinoma cell migration, invasion and epithelial mesenchymal transition, reduce macrophage secretion of vascular endothelial growth factor C, and effectively inhibit tumor growth and lymphatic metastasis in a naked mouse popliteal lymph node metastasis model and a spontaneous cholangiocarcinoma model. The compound presents a synergistic effect in combination with gemcitabine and cisplatin.

The present invention pertains to a new method for the diagnosis, prognosis, stratification and / or monitoring of a therapy, of a pulmonary dysfunction in a subject. The method is based on the determination of the level of a panel of biomarkers selected from TM4SF18, TRGV9, ADORA2A, H963, IRF2, TNFSF14, TRIB1, SMAD3, TSLP, SLAMF8, THBS1, SOD1, HAS2, TLR2, THBD, TRA, TFEC, SPHK1, COL3A1, Elastin, IL6R, SN, TEK, SOX7, CXCL9, CXCL10, SLC38A6, SLC15A3, TGFA, SLPI, VWF, TLR8, TGFB1, CXCR6, CCL24, PD1, PLA1A, TRD, CTLA4, MMP9, CD301, PDL1, PDL2, TGFB1, CXCR6, CCL24, PD1, PLA1A, TRD, CTLA4, MMP9, and CD301. The new biomarker panels of this invention allow diagnosing and even stratifying various pulmonary dysfunctions in a subject, and even allow early detection of Chronic lung allograft dysfunction (CLAD). Furthermore provided are diagnostic kits for performing the methods of the invention.

Peptide fragments of Amuc_1100* and uses thereof are disclosed. The peptides are shown to be ligands that activate TLR2 and are useful in the treatment of obesity and related diseases or disorders. The peptides of the invention are further useful in the treatment of small intestinal cancer, in the promotion of immune responses, and in intestinal epithelial barrier dysfunction.

The present invention belongs to the technical field of biomedicine, and specifically relates to an intracellular signaling domain of a chimeric antigen receptor and the use thereof. The intracellular signaling domain comprises at least two of a1)-a7): a1) FCE or a portion thereof; a2) CD3ζ or a portion thereof; a3) CD40 or a portion thereof; a4) TLR2 or a portion thereof; a5) TLR4 or a portion thereof; a6) IFNgR or a portion thereof; and a7) PI3Krecruit or a portion thereof. The chimeric antigen receptor comprising the intracellular domain can maintain a CAR-positive rate while ensuring the viability and recovery yield of immune cells, thereby better ensuring the activity of CAR-immune cells. Immune cells expressing the chimeric antigen receptor comprising the intracellular domain exhibit significantly enhanced phagocytic, cytotoxic and anti-exhaustion capacities in addition to T cell activation level, thereby achieving more potent antitumor activity and enhanced tumor infiltration.

Methods, compounds, compositions, and kits for the treatment of cancer, comprising TLR2 agonists, particularly dipalmitoyl-S- glyceryl-cysteine (Pam2Cys) derivatives and conjugates, are provided. In one aspect, methods of treating, preventing or minimizing the progression of cancer comprising the administration of a compound comprising a Pam2Cys moiety and a polyethylene glycol (PEG) are provided.

Methods, compounds, compositions and kits for the treatment and / or prevention of cancer are provided. In particular, methods for the treatment of cancer comprising the administration of a TLR2 agonist, such as a conjugate of dipalmitoyl-S-glyceryl-cysteine (Pam2Cys) and polyethylene glycol (PEG), more particularly a Pam2Cys-Ser-PEG compound, and an immunostimulant such as an anti-PD-1, anti-PDL-1, anti-PL- 1, or anti-CTLA-4 immunotherapeutic, are provided.